Vanta Bioscience Share News - Latest Updates, Live News & More

Latest news about Vanta Bioscience

Vanta Bioscience turns profitable in FY26 with revenue up ~61% 4 days ago

Standalone PAT turned to Rs. 1,198.11 thousand in FY26 from a loss of Rs. 26,594.08 thousand in FY25. Standalone revenue from operations rose approximately 61.11% to Rs. 18,163.64 thousand in FY26 from Rs. 11,274.22 thousand in FY25. 8,00,000 equity shares allotted on preferential basis at Rs. 10/- face value and Rs. 40/- premium, raising paid-up capital to Rs. 7,11,20,000/-. 10th AGM scheduled for September 30, 2026; re-appointment of Managing Director Dopesh Raja Mulakala for three years proposed at up to Rs. 2,50,000/- per month. Auditors flagged non-provision for gratuity and outstanding statutory dues; subsidiary Vanta Clinical Research Limited yet to commence operations.

Vanta warns of AI security chaos as employee builder roles surge 300% Aug 22, 2026

Vanta achieves FedRAMP 20x Class C Certification for Government Cloud Jul 10, 2026

Vanta Bioscience board to consider FY26 audited results on May 30 May 26, 2026

Vanta Bioscience Limited Submits SEBI Compliance Certificate for Q4FY26 Apr 10, 2026

More news about Vanta Bioscience

11Mar 26

Vanta Bioscience Limited Responds to BSE Inquiry on Share Price Movement

Vanta Bioscience Limited has clarified to BSE Limited that recent share price movements are market-driven, following a regulatory inquiry dated 25.02.2026. The company confirmed compliance with SEBI Listing Regulations and stated that all material information affecting operations has been disclosed within required timeframes. Management emphasized they are unaware of specific reasons for price movement and reiterated commitment to regulatory compliance.

30Jan 26

Vanta Bioscience Appoints Ms. Pooja Kothari as Company Secretary and Compliance Officer

Vanta Bioscience Limited appointed Ms. Pooja Kothari as Company Secretary and Compliance Officer effective January 30, 2026, following board approval. Ms. Kothari, an ICSI Associate Member with 4 years of experience in Company Law and Secretarial Compliances, brings expertise from working with private and unlisted public companies. The appointment complies with SEBI regulations and strengthens the company's governance framework.

05Sept 25

Vanta Bioscience Faces Insolvency Application Over Unpaid Salary Claims

Vanta Bioscience Limited is facing an insolvency application filed by S Venkata Rao, its former Whole Time Director & CEO, under Section 9 of the Insolvency and Bankruptcy Code, 2016. Rao alleges the company defaulted on salary and interest payments totaling Rs. 1.18 crore. Vanta Bioscience denies all allegations, calling them baseless, and has sought legal advice to protect its interests. The company states it has not received any communications from NCLT regarding this matter.

01Aug 25

Vanta Bioscience Reports Significant Losses for FY2025 Amid Revenue Decline

Vanta Bioscience Limited, a preclinical contract research organization, reported a substantial net loss for FY2025. Standalone net loss was Rs 265.95 lakh, compared to a profit of Rs 5.11 lakh in the previous year. Revenue from operations declined by 86.80% to Rs 112.74 lakh. Consolidated results showed a net loss of Rs 477.49 lakh, with revenue falling by 79.80% to Rs 196.36 lakh. The company faced operational challenges, including delays in consolidating financial results due to late receipt of accounts from an associate company. Despite financial difficulties, total assets increased by 2.52% to Rs 52.90 crore, while current liabilities rose by 39.22% to Rs 14.20 crore.

Vanta Bioscience

19.56

0.0

(0.0%)

1 Year Returns:-15.36%

Industry Peers

Syngene International

379.90

(+0.32%)

Indegene

608.95

(0.0%)

Suven Life Sciences

335.90

(+0.27%)

Vimta Labs

601.00

(+0.28%)

Bilcare

100.72

(-1.99%)

TAKE

15.48

(-0.19%)

Jeevan Scientific Technology

79.77

(0.0%)

Adeshwar Meditex

16.89

(0.0%)

Vanta Bioscience

19.56

(0.0%)

Get More Market Insights with

Stock Rental via SLBM

About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.

Part of Raise Financial Services

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357 Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104